Inari Medical today announced a definitive agreement to purchase LimFlow Medical for up to $415 million. The deal comes just weeks after Paris-based LimFlow won FDA premarket approval (PMA) for its breakthrough system to treat chronic limb-threatening ischemia (CLTI). San Jose, California–based Inari said it expects to complete the acquisition by the end of 2023. […]
